We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Advancing the Identification of Novel Biomarkers
Product News

Advancing the Identification of Novel Biomarkers

Advancing the Identification of Novel Biomarkers
Product News

Advancing the Identification of Novel Biomarkers


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Advancing the Identification of Novel Biomarkers"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Thermo Fisher Scientific and Owlstone Medical, developer of the Breath Biopsy platform for applications in early disease detection and precision medicine, have entered into a collaborative partnership to advance the early diagnosis of cancer and other diseases through the discovery and validation of novel biomarkers by non-invasive breath sampling.

Through the integration of Orbitrap gas chromatography mass spectrometry (GC-MS) instrumentation into Owlstone Medical’s Breath Biopsy platform, the collaboration will qualify Thermo Fisher’s mass analyzers for the detection of new biomarkers via a validated discovery and routine analysis project. Developed in partnership, the new analytical methods will be used to conduct metabolomics studies of breath samples for unique biomarkers that could translate into non-invasive, routine screening solutions for improved early diagnosis of cancer and other disease.

"There is a growing need for non-invasive diagnostic solutions to support early disease detection, patient treatment and increase remission rates," said Morten Bern, director of marketing, gas chromatography, Thermo Fisher Scientific. "The combination of our Orbitrap GC-MS technology with Owlstone Medical’s Breath Biopsy platform provides a unique basis to improve patient outcomes through the discovery of novel biomarkers and their incorporation into research use and clinical tests."

Billy Boyle, co-founder and chief executive officer at Owlstone Medical, said: "The Orbitrap platform’s ability to detect a wide range of chemicals during targeted and untargeted analyses without losing selectivity or sensitivity, promises to be of substantial benefit to our Breath Biopsy platform. With a large and rapidly expanding installed base of GC Orbitrap systems, our collaboration with Thermo Fisher Scientific represents an exciting opportunity for cross-promotion of the platform and technique, by which the benefits of Breath Biopsy can be broadly realized."

Advertisement